OncoMatch/Clinical Trials/NCT07763054
Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients
Is NCT07763054 recruiting? Yes, currently enrolling (Sep 2026). Studying Liposomal Amphotericin B for acute myeloid leukemia.
Treatment: Liposomal Amphotericin B — This is a single-center, single-arm, observational clinical study evaluating the efficacy and safety of low-dose liposomal amphotericin B (50 mg/day, intravenous, once daily) for the prevention of invasive fungal infections in adult patients (aged 18-75 years) with hematological malignancies who develop prolonged neutropenia (absolute neutrophil count ≤0.5×10\^9/L, expected to last \>7 days) and are at high risk for invasive fungal disease. Participants are those who, per the treating physician's routine clinical decision, have been initiated on liposomal amphotericin B prophylaxis at 50 mg/day due to intolerance or toxicity to other antifungal agents. The primary outcome is the incidence of proven or probable invasive fungal disease. Secondary outcomes include incidence of pneumonia, persistent unexplained fever \>4 days, use of additional systemic antifungal therapy, and adverse events. A total of 30 participants will be enrolled. Data will be collected at baseline, during treatment, and within 7 days after treatment completion.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Primary Central Nervous System Lymphoma
Multiple Myeloma
Chronic Lymphocytic Leukemia
Demographics
Prior therapy
Cannot have received: antifungal therapy for invasive fungal disease
Prior history of proven or probable invasive fungal disease (IFD)
Lab requirements
Blood counts
Agranulocytosis: ANC ≤0.5×10^9/L, or ANC ≤1×10^9/L with expected decline to ≤0.5×10^9/L within 48 hours
Kidney function
No renal impairment requiring or currently undergoing hemodialysis or peritoneal dialysis
Liver function
AST or ALT <5× ULN; total bilirubin <3× ULN
Cardiac function
No NYHA Class III/IV heart failure
Clinically significant hypokalemia (serum potassium <3.2 mmol/L, or below LLN while receiving digitalis) that cannot be corrected before starting trial treatment. Hepatic dysfunction with AST or ALT ≥5× ULN, or total bilirubin ≥3× ULN. Renal impairment requiring or currently undergoing hemodialysis or peritoneal dialysis. NYHA Class III/IV heart failure.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07763054 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior antifungal therapy for invasive fungal disease disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify